Driver Domains in Persistent Atrial Fibrillation
The ablation of persistent atrial fibrillation (AF) remains suboptimal mainly because of the complexity of the underlying mechanisms, including substrate remodeling. The present study evaluates a noninvasive phase-based signal processing capable of visualizing atrial waves propagating during AF; focal breakthroughs or reentrant sources at the origin of such waves were defined as AF drivers. The principal finding is that persistent AF is mechanistically sustained by a few individual driving regions in the early months of persistent AF. Drivers were mostly localized unstable reentries possibly anchored on to local tissue heterogeneity. The high rate of termination of AF was observed from limited catheter ablation. The patients presenting in sinus rhythm also have a favorable outcome of ablation targeting drivers alone, presumably because of the limited structural substrate. With prolongation in the duration of AF, the substrate disseminated, making AF a ubiquitous electrostructural disorder and its termination rate sharply declined. In the absence of perprocedural remapping, it is unknown whether the nontermination of AF was attributable to the emergence of new AF drivers or multiple wavelets. In summary, the study indicates that persistent AF in early months is maintained predominantly by drivers clustered in a few regions, most of them being unstable reentries. See p 530.
Effect of Bilateral Internal Mammary Artery Grafts on Long-Term Survival: A Meta-Analysis Approach
The clinical benefit of single internal mammary artery in reducing 10-year mortality, myocardial infarction, recurrent angina, and the need for repeat intervention was established almost 3 decades ago. Since then, a considerable body of evidence has demonstrated the marked angiographic superiority of both internal mammary arteries in comparison with vein grafts at up to 2 decades of follow-up. Similarly, several individual studies have reported superior long-term survival with bilateral internal mammary arteries in comparison with a single mammary artery. The present meta-analysis, of almost 16 000 patients with a median follow-up of >9 years, provides additional support for a significant survival advantage of 2 internal mammary arteries at up to a decade of follow-up. However, currently <5% of patients in the United States and <10% of patients in Europe undergoing coronary artery bypass grafting receive 2 internal mammary arteries. The present study strongly implies that there should be far wider routine use of 2 internal mammary arteries in patients undergoing surgical revascularization. See p 539.
Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)
National and international guidelines recommend fasting lipid panel measurement for risk stratification. However, the prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol is uncertain. Using data from the National Health and Nutrition Examination Survey (NHANES), we found that fasting low-density lipoprotein cholesterol yielded prognostic value similar to that of nonfasting low-density lipoprotein cholesterol for all-cause mortality (C statistics 0.59 [95% confidence interval, 0.57-0.61] versus 0.58 [95% confidence interval, 0.56-0.60; P=0.73) as well as cardiovascular mortality (fasting versus nonfasting C statistics 0.62 [95% confidence interval, 0.60-0.66] versus 0.62 [95% confidence interval, 0.60-0.66]; P=0.96; P interaction =0.34). This study shows similar prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol on long-term mortality in a nationally representative US cohort. National and international agencies should consider reevaluating the recommendation that patients fast before a lipid panel is obtained. See p 546.
Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients
Obesity and diabetes mellitus are independently associated with the development of heart failure. In this study, we determined the respective effects of obesity, insulin resistance, and diabetes mellitus on intrinsic contraction and mitochondrial function of the human myocardium before the onset of cardiomyopathy. Exploring right atrial human samples, we show that diabetes mellitus is associated with a pronounced impairment of intrinsic contraction, mitochondrial dysfunction, and increased myocardial oxidative stress, regardless of weight status. These effects in diabetic hearts are associated with a fragmentation of the mitochondrial network and decreased expression of the MFN1 protein involved in mitochondrial fusion. In contrast, obesity was associated with less pronounced contractile dysfunction without any significant perturbation of mitochondrial function or oxidative stress status. Tested as continuous variables, glycated hemoglobin, but not body mass index or insulin resistance (homeostasis model assessment-insulin resistance), was independently associated with cardiac mitochondrial function. On the basis of the present findings, worsening of intrinsic myocardial contraction in the transition from obesity to diabetes mellitus is likely related to worsening of cardiac mitochondrial function because impaired mitochondrial function and dynamics and contractile dysfunction are observed in diabetic patients but not in "metabolically healthy" obese patients at early stages of insulin resistance. Moreover, chronic hyperglycemia is postulated to be a major driver of both mitochondrial dysfunction and mitochondrial network fragmentation in the human diabetic heart. This study opens a research field for potential therapies to prevent heart failure in diabetic patients by targeting the mitochondria. See p 554.
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Epigenome-Wide Association Study of Fasting Blood Lipids in the Genetics of Lipid-Lowering Drugs and Diet Network Study
The findings implicate a role for CPT1A methylation in interindividual variation in triglycerides and very-low lowdensity lipoprotein cholesterol beyond DNA sequence variants. Specifically, we report strong association between methylation in the promoter region of CPT1A in CD4+ T cells and triglycerides and very-low low-density lipoprotein cholesterol in >900 healthy white adults from the Genetics of Lipid Lowering Drugs and Diet Network Study (GOLDN). Common genetic variation did not underlie the epigenetic signal in GODLN and resequencing studies validated the array findings for the top cytosine-(phosphate)-guanine site.
Results were robustly replicated in >1200 adults from the Framingham Heart Study (FHS) by using DNA from buffy coat preparations. The top cytosine-(phosphate)-guanine site was associated with gene expression in both populations. Because we found that methylation at this site alters gene expression, our findings suggest future lipid-lowering treatment could alter expression or action of CPT1A. However, our findings are based on cross-sectional data in healthy white populations, and further research is needed before CPT1A can be targeted for drug development. Importantly, further replication can expand the generalizability of our results to other ethnic and clinical populations. Longitudinal studies are needed to determine whether the observed associations are attributable to methylation effects on lipids or vice versa. Finally, the functional mechanism of methylation variation on gene expression also needs further evaluation. In summary, the current study represents a promising finding in genomics for the potential future treatment of hypertriglyceridemia, but much additional work is needed before drug development can ensue. See p 565.
